- Home
- ALHC vs TVTX Comparison
ALHC vs TVTX Comparison
Compare ALHC & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALHC | TVTX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 2.8B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ALHC | TVTX |
|---|---|---|
| Price | $20.86 | $40.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $23.00 | ★ $40.46 |
| AVG Volume (30 Days) | ★ 3.2M | 1.9M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,948,719,000.00 | N/A |
| Revenue This Year | $33.69 | $43.88 |
| Revenue Next Year | $24.74 | $33.16 |
| P/E Ratio | $405.00 | ★ N/A |
| Revenue Growth | ★ 46.06 | N/A |
| 52 Week Low | $11.63 | $13.88 |
| 52 Week High | $23.87 | $43.31 |
Technical Indicators
Market Signals| Indicator | ALHC | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 73.43 |
| Support Level | $19.93 | $32.62 |
| Resistance Level | $23.31 | $41.44 |
| Average True Range (ATR) | 0.89 | 2.07 |
| MACD | 0.39 | 1.25 |
| Stochastic Oscillator | 70.78 | 87.06 |
Price Performance
Historical ComparisonAbout ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.